医療用特殊酵素の世界市場2020-2027:ソース別(カルボヒドラーゼ、プロテアーゼ)、製品別、技術別、用途別、使用別、エンドユーザー別、地域別

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Significant developments in the research and biotechnology space
3.1.1.2 Technological advancements in enzyme-based monitoring
3.1.1.3 Rising demand for specialty enzymes in the prognosis of diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Risks associated with an enzyme-based diagnosis
3.2 Penetration & Growth Prospect Mapping for Product, 2019
3.3 Healthcare Specialty Enzymes Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis – Porter’s
3.5 Enzyme Manufacturing Industry: Recent Trends
3.5.1 Enzyme Manufacturing Industry Scenario For Developing Economies
3.5.1.1 Key recommendations for the enzyme manufacturing in developing economies
Chapter 4 Healthcare Specialty Enzymes: Product Business Analysis
4.1 Healthcare Specialty Enzymes Market: Product Movement Analysis
4.2 Carbohydrases
4.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
4.3 Polymerases and Nucleases
4.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
4.4 Protease
4.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
4.5 Lipases
4.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
4.6 Phosphatases/Phytases
4.6.1 Market estimates and forecast, 2016 – 2027 (USD Million)
4.7 Other Products
4.7.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 5 Healthcare Specialty Enzymes: Source Business Analysis
5.1 Market: Source Movement Analysis
5.2 Microorganisms
5.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.3 Animals
5.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.4 Plants
5.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 6 Healthcare Specialty Enzymes: Technique Business Analysis
6.1 Market: Technique Movement Analysis
6.2 Clinical Chemistry
6.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.3 Molecular Diagnostics
6.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.4 Immunodiagnostics
6.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.5 Microbiology
6.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.6 Hematology
6.6.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 7 Healthcare Specialty Enzymes: Usage Estimates & Trend Analysis
7.1 Market: Usage Movement Analysis
7.2 Research & Biotechnology
7.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
7.3 Diagnosis
7.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 8 Healthcare Specialty Enzymes: Application Business Analysis
8.1 Market: Application Movement Analysis
8.2 Infectious Disease
8.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.3 Diabetes
8.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.4 Oncology
8.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.5 Cardiology
8.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.6 Nephrology
8.6.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.7 Autoimmune diseases
8.7.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 9 Healthcare Specialty Enzymes: End-use Business Analysis
9.1 Market: End-use Movement Analysis
9.2 Hospitals
9.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.3 Laboratory
9.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.4 Others
9.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 10 Healthcare Specialty Enzymes: Regional Business Analysis
10.1 Market: Regional Movement Analysis
10.2 North America
10.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.2.2 U.S.
10.2.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.2.3 Canada
10.2.3.1 Market estimates and forecast, 2016 – 2027 (USD million)
10.3 Europe
10.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.3.2 Germany
10.3.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.3.3 U.K.
10.3.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.4 Asia Pacific
10.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.4.2 China
10.4.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.4.3 India
10.4.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.4.4 Japan
10.4.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.5 Latin America
10.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.5.2 Brazil
10.5.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.6 Middle East and Africa (MEA)
10.6.1 Market estimates and forecast, 2016 – 2027 (USD Million)
10.6.2 South Africa
10.6.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 11 Company Profile
11.1 Strategy Framework
11.2 Market Participation Categorization
11.3 Company Profiles
11.3.1 Advanced Enzymes Technologies Ltd.
11.3.1.1 Company Overview
11.3.1.2 Financial Performance
11.3.1.3 Product Benchmarking
11.3.1.4 Strategic Initiatives
11.3.2 Amano Enzymes, Inc.
11.3.2.1 Company Overview
11.3.2.2 Financial Performance
11.3.2.3 Product Benchmarking
11.3.2.4 Strategic Initiatives
11.3.3 Amicogen
11.3.3.1 Company Overview
11.3.3.2 Financial Performance
11.3.3.3 Product Benchmarking
11.3.3.4 Strategic Initiatives
11.3.4 BBI Solutions
11.3.4.1 Company Overview
11.3.4.2 Financial Performance
11.3.4.3 Product Benchmarking
11.3.5 biotechrabbit GmbH
11.3.5.1 Company Overview
11.3.5.2 Financial Performance
11.3.5.3 Product Benchmarking
11.3.5.4 Strategic Initiatives
11.3.6 Brain AG
11.3.6.1 Company Overview
11.3.6.2 Financial Performance
11.3.6.3 Biocatalysts
11.3.6.3.1 Company Overview
11.3.6.3.2 Product Benchmarking
11.3.6.3.3 Strategic Initiatives
11.3.7 CPC Biotech
11.3.7.1 Company Overview
11.3.7.2 Financial Performance
11.3.7.3 Product Benchmarking
11.3.7.4 Strategic Initiatives
11.3.8 Creative Enzymes
11.3.8.1 Company Overview
11.3.8.2 Financial Performance
11.3.8.3 Product Benchmarking
11.3.8.4 Strategic Initiatives
11.3.9 EKF Diagnostics
11.3.9.1 Company Overview
11.3.9.2 Financial Performance
11.3.9.3 Product Benchmarking
11.3.9.4 Strategic Initiatives
11.3.10 F. Hoffmann-La Roche Ltd
11.3.10.1 Company Overview
11.3.10.2 Financial Performance
11.3.10.3 Custom Biotech
11.3.10.3.1 Company Overview
11.3.10.3.2 Product Benchmarking
11.3.11 Merck Group/KGaA
11.3.11.1 Company Overview
11.3.11.2 Sigma-Aldrich (Millipore Sigma)
11.3.11.2.1 Product Benchmarking
11.3.11.3 Financial Performance
11.3.11.4 Strategic Initiatives
11.3.12 Sekisui Chemical Co., Ltd.
11.3.12.1 Company Overview
11.3.12.2 Financial Performance
11.3.12.3 Strategic Initiatives
11.3.12.4 Sekisui Medical Co., Ltd
11.3.12.4.1 Company Overview
11.3.12.4.2 Sekisui Diagnostics
11.3.13 Thermo Fisher Scientific, Inc.
11.3.13.1 Company Overview
11.3.13.2 Financial Performance
11.3.13.3 Product Benchmarking
11.3.13.4 Strategic Initiatives

グローバル市場調査会社